109173 ⎘
Structure or type of the nucleic acid; Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
MICRORNA-134 BIOMARKER
#2OLIGONUCLEOTIDES
#3COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEUKODYSTROPHY AND WHOLE ANIMAL AND CELLULAR MODELS FOR IDENTIFYING EFFICACIOUS AGENTS FOR TREATMENT OF THE SAME
#4SMALL RNA-BASED PROGNOSTIC SIGNATURES AND THERAPEUTIC COMPOSITIONS FOR IDIOPATHIC PULMONARY FIBROSIS
#5COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#6METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY TARGETING ONCOGENIC TRANSFER RNAS
#7STABILIZED RNA AGENTS
#8COMPOSITIONS AND METHODS TO MODULATE TUMOR MICROENVIRONMENT ASSOCIATED LONG NONCODING RNAS
#9MODIFIED DOUBLE-STRANDED RNA AGENTS
#10Oral Delivery of Antisense Conjugates Targeting PCSK9
#11OLIGONUCLEOTIDES FOR MODULATING REGULATORY T CELL MEDIATED IMMUNOSUPPRESSION
#12METHODS AND COMPOSITIONS FOR MODULATING SPLICING AT ALTERNATIVE SPLICE SITES
#13REVERSIR MOLECULES AND METHODS OF USE THEREOF
#14TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
#15METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#16ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS
#17Oligonucleotide for reducing the expression of leucine-rich repeat kinase 2 (LRRK2) and its use for preventing and/or treating human diseases
#18COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#19ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF
#20METHODS AND COMPOSITIONS FOR SELECTIVELY MODULATING GENE EXPRESSION IN MEGAKARYOCYTES AND PLATELETS
#21COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER BY TARGETING THE BRCA1 PSEUDOGENE (BRCA1P1)
#22ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS
#23COMPOSITIONS AND METHODS FOR TREATING PANCREATIC CANCER
#24OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION
#25COMPOUNDS AND METHODS FOR REDUCING PRION EXPRESSION
#26OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
#27DETECTION ASSAYS
#28METHODS AND COMPOSITIONS FOR INHIBITING VIRUS
#29THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF
#30Selective Antisense Compounds and Uses Thereof
#31MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUS
#32Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#33OLIGONUCLEOTIDES
#34MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHY
#35NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES
#36Antisense Compounds Targeted to CLN3 and Uses Thereof
#37MODIFIED ANTISENSE OLIGONUCLEOTIDES TARGETING FOXG1
#38PRIME EDITING OF SINGLE BASE MUTATIONS IN ALPHA-1 ANTITRYPSIN DEFICIENCY
#39Modified Compounds and Uses Thereof
#40COMPOSITIONS COMPRISING PLN-TARGETING ANTI-TRANSFERRIN RECEPTOR ANTIBODY-POLYNUCLEOTIDES AND METHODS OF USE THEREOF TO TREAT CARDIOMYOPATHY
#41CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#42TARGETING MICRO RNA FOR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)
#43Antisense Oligonucleotide for Targeting Progranulin
#44COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#45COMPOUNDS AND METHODS FOR REDUCING PCDH19 EXPRESSION
#46COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION
#47METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
#48APTAMER-BASED MINERAL AND METAL COLLECTION
#49Conjugated Antisense Compounds and Their Use
#50TREATMENT OF SOS2 RELATED DISEASES AND DISORDERS
#51TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF
#52Targeting Skin-Related Conditions Using Bottlebrush Polymer-Conjugated Oligonucleotides
#53ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
#54COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES
#55MODULATION OF ABCB11 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#56NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION
#57COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS
#58COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13A
#59EDITING OLIGONUCLEOTIDE
#60OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF
#61SPLICE-SWITCHING OLIGONUCLEOTIDES
#62COMPOUNDS AND METHODS FOR MODULATING ATXN1
#63CERTAIN DUX4 INHIBITORS AND METHODS OF USE THEREOF
#64USE OF ANTISENSE OLIGONUCLEOTIDE IN PREPARATION OF DRUG FOR TREATING DISEASE CAUSED BY ABNORMAL THYROID
#65MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#66IMPROVED OLIGONUCLEOTIDES TARGETING RNA BINDING PROTEIN SITES
#67MAPT ANTISENSE OLIGONUCLEOTIDE
#68COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13A
#69Compositions for Treatment of Polycystic Kidney Disease
#70ENHANCED HAMMERHEAD RIBOZYMES AND METHODS OF USE
#71COMPOSITIONS AND METHODS RELATED TO MULTIPLE MYELOMA-ASSOCIATED LONG NONCODING RNAS
#72INHIBITORS OF MIR-221 FOR THE TREATMENT OF SOLID NEOPLASMS AND PERIPHERAL NEUROTOXICITY INDUCED BY ANTICANCER DRUGS AND OTHER NEUROLOGICAL DISEASES RELATED TO MIR-221
#73Novel CRISPR gRNAs
#74ANTI-CANCER AGENTS
#75COMPOUNDS AND METHODS FOR MODULATING SCN2A
#76Selective Antisense Compounds and Uses Thereof
#77TARGETED INHIBITION OF REVERSE TRANSCRIPTION USING ANTISENSE OLIGOS
#78COMPOSITIONS AND METHODS OF MODULATING RNA AND PROTEIN INTERACTIONS
#79SIGNAL ACTIVATABLE NUCLEIC ACID COMPLEXES
#80REVERSIR TM COMPOUNDS
#81MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#82TRANSLATION ENHANCING NUCLEIC ACID COMPOUNDS: ASO COUPLED TRANSLATION – UPREGULATION 1 (ACT-UP1) AND USES THEREOF
#83DOSING OF MUSCLE TARGETING COMPLEXES FOR TREATING MYOTONIC DYSTROPHY
#84Oligonucleotides
#85CARBOCYCLIC NUCLEOSIDE, OLIGONUCLEOTIDE AND PREPARATION METHODS THEREFOR AND MEDICAL USES THEREOF
#86Selective Reduction of Allelic Variants
#87OLIGONUCLEOTIDES WITH 2'-DEOXY-2'-F-2'-C-METHYL NUCLEOTIDES
#88MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#89SINGLE-STRAND FORM POLYNUCLEOTIDE AND USE THEREOF IN GENOME EDITING
#90TARGETED CELL SELECTION AND RELEASE USING APTAMER COMPLEXES IN A CELL PROCESSING SYSTEM
#91LNCRNA TRANSCRIPTS IN MELANOMAGENESIS
#92METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
#93METHODS OF DESIGNING CONDITIONAL-ACTIVATABLE SMALL INTERFERING RNA SENSORS
#94siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2
#95CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITY
#96NONCOVALENTLY BRANCHED OLIGONUCLEOTIDE COMPOSITIONS
#97MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS
#98ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
#99SIGNAL ACTIVATABLE NUCLEIC ACID CONSTRUCTS WITH WOBBLE BASE PAIRINGS
#100METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS
#101NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
#102Brush polymer-oligonucleotide conjugates for the treatment of muscular dystrophy
#103COMPOSITIONS AND METHODS FOR IMPROVING STRAND BIASED
#104LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
#105OLIGONUCLEOTIDES TARGETING RNA BINDING PROTEIN SITES
#106ANTISENSE OLIGONUCLEOTIDES TARGETING ADENOSINE KINASE
#107ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
#108CHANNEL MODULATORS
#109OLIGONUCLEOTIDE AGONISTS TARGETING PROGRANULIN
#110Composition and Methods for Modulating Nuclear Enriched Abundant Transcript 1 to Treat Cognitive Impairment
#111MODULATION OF ALPHA SYNUCLEIN EXPRESSION
#112MODULATION OF MICRORNA-335-5P FOR THE TREATMENT OF SODIUM CHANNELOPATHIES
#113COMPOSITIONS AND METHODS FOR PREPARING CAPPED CIRCULAR RNA MOLECULES
#114MICRORNA INHIBITOR THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS
#115OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
#116COMPOUNDS FOR INHIBITION OF IL-1BETA EXPRESSION
#117MODULATING THE CELLULAR STRESS RESPONSE
#118COMPOUNDS FOR INHIBITING AMANZI
#119EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6
#120ANTISENSE OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTION OR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA
#121ADVANCED RNA TARGETING (ARNATAR)
#122CHEMICALLY MODIFIED ANTISENSE OLIGONUCLEOTIDES (ASOS) AND COMPOSITIONS COMPRISING THE SAME FOR RNA EDITING
#123Modified Oligonucleotides and Methods of Use
#124GUIDE RNA WITH CHEMICAL MODIFICATIONS
#125COMPOSITIONS COMPRISING THERAPEUTIC NUCLEIC ACID AND TARGETED SAPONIN FOR THE TREATMENT OF MUSCLE-WASTING DISORDERS
#126ACVR1R206H ALLELE-SPECIFIC THERAPY AND USES THEREOF FOR TREATMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
#127ANTI-SENSE OLIGONUCLEOTIDES AND USES THEREOF
#128COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
#129MODULATORS OF APOL1 EXPRESSION
#130THERAPEUTIC OLIGONUCLEOTIDES
#131METHODS AND AGENTS FOR INCREASING RBM3 EXPRESSION
#132NLRP3 oligonucleotide for use in preventing and/or treating an inflammatory disease
#133ANTISENSE OLIGONUCLEOTIDES (ASOS) THAT SUPPRESS SARS-COV-2 REPLICATION
#134THERAPEUTIC OLIGONUCLEOTIDES HAVING AN INTER-NUCLEOSIDE AMIDE LINKAGE
#135TUNABLE REVERSIR TM COMPOUNDS
#136OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
#137COMPOSITIONS AND METHODS OF MODULATING LONG NONCODING TRANSCRIPTS ASSOCIATED WITH ARDS INDUCED PULMONARY FIBROSIS
#138THERAPEUTICS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
#139Antisense Oligonucleotide for Targeting Progranulin
#140TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF UNC13A GENE TRANSCRIPTS
#141TREATMENT OF FGG RELATED DISEASES AND DISORDERS
#142MODIFIED DOUBLE-STRANDED RNA AGENTS
#143ANTISENSE OLIGONUCLEOTIDE DRUG TARGETS
#144COMPOSITIONS AND METHODS OF USING PLN-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
#145METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION
#146NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TMPRSS6 AND IRON CHELATORS
#147THERAPEUTIC NUCLEIC ACIDS AND METHODS OF USE THEREOF
#148IRNA COMPOSITIONS AND METHODS FOR SILENCING COMPLEMENT COMPONENT 3 (C3)
#149LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#150COMPOSITIONS AND METHODS FOR ENHANCING GENE SILENCING ACTIVITY OF OLIGONUCLEOTIDE COMPOUNDS
#151NUCLEIC ACID AGENTS FOR TREATMENT OF NON-SMALL-CELL LUNG CANCER
#152Means and Methods for Chronic Wound Healing
#153NUCLEIC ACID-CONTROLLED CATALYTIC RNAS FOR TRIGGER-RESPONSIVE REGULATION
#154Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
#155TIS-L TARGETING ANTIVIRAL ANTISENSE OLIGONUCLEOTIDE WITH ABILITY TO INHIBIT VIRAL REPLICATION OF SARS-COV-2
#156COMPOSITIONS AND METHODS FOR SKIPPING EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY
#157ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN
#158MODIFIED DOUBLE-STRANDED RNA AGENTS
#159COMBINATION OF OLIGONUCLEOTIDES FOR MODULATING RTEL1 AND FUBP1
#160COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION
#161PREVENTIVE OR THERAPEUTIC AGENT FOR BENIGN ADULT FAMILIAL MYOCLONIC EPILEPSY
#162COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#163THERAPEUTICS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
#164BIOLOGICALLY STABLE XNAZYME THAT EFFICIENTLY SILENCES GENE EXPRESSION IN CELLS
#165TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
#166COMPOSITIONS AND METHODS FOR MODULATING KRAS EXPRESSION
#167ANGPTL4 OLIGONUCLEOTIDES INFLUENCING THE REGULATION OF THE FATTY ACID METABOLISM
#168Oligonucleotides
#169APTAMERS FOR TARGETED ACTIVATION OF T CELL-MEDIATED IMMUNITY
#170ANTISENSE OLIGONUCLEOTIDES FOR MODULATING TMEM106B EXPRESSION
#171ANTISENSE COMPOUND FOR MODULATING WFDC2 EXPRESSION
#172Conditional Double Stranded Antisense Oligonucleotides
#173USE OF microRNA MIMICS TO INHIBIT OR TREAT LIVER DISEASE
#174OLIGONUCLEOTIDES COMPRISING SEGMENTED GAP STRUCTURES
#175DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDES
#176GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
#177Selective Antisense Compounds and Uses Thereof
#178METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#179MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#180LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
#181Compositions and methods for modulating apolipoprotein (a) expression
#182TREATMENT FOR TYROSINE DEGRADATION-ASSOCIATED DISORDERS
#183NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
#184Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
#185COMPOUNDS AND METHODS FOR REDUCING DUX4 EXPRESSION
#186Compounds and Methods for Reducing DMPK Expression
#187ANTISENSE OLIGONUCLEOTIDES TARGETING UNC13A
#188MODULATORS OF ENaC EXPRESSION
#189OLIGONUCLEOTIDES TARGETING RNA BINDING PROTEIN SITES
#190METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME
#191METHODS OF GENERATING CORE STRANDS IN CONDITIONALLY ACTIVATABLE NUCLEIC ACID COMPLEXES
#192MODULATION OF PREKALLIKREIN (PKK) EXPRESSION
#193ANTISENSE OLIGONUCLEOTIDES TARGETING ACTL6B
#194CRISPR-BASED COMPOSITIONS AND METHODS OF USE
#195COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#196COMPOSITIONS FOR MODULATING ATAXIN 2 EXPRESSION
#197METABOLIC DISORDER-ASSOCIATED TARGET GENE IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#198COMPOUNDS FOR MODULATING UNC13A EXPRESSION
#199MICRORNA-134 INHIBITORS
#200Chemically Modified Small Activating RNA
#201METHODS OF PLACING LOCKED NUCLEIC ACIDS IN SMALL INTERFERING RNA STRANDS
#202ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION
#203Selective Antisense Compounds and Uses Thereof
#204MODULATION OF NOX4 EXPRESSION
#205Oligonucleotides for Modulating Apolipoprotein E4 Expression
#206AGENTS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF HYPOXIA AND ISCHEMIA-RELATED DISORDERS
#207NOVEL PROCESSES FOR THE PRODUCTION OF OLIGONUCLEOTIDES
#208TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
#209COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#210TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS
#211TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS
#212RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA)
#213OLIGONUCLEOTIDES
#214Conjugated antisense compounds and their use
#215Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors
#216LIGAND-BINDING NUCLEIC ACID COMPLEX
#217COMPOUNDS FOR REDUCING PTBP1 EXPRESSION
#218OLIGONUCLEOTIDES AND COMPOSITIONS THEREOF FOR NEUROMUSCULAR DISORDERS
#219MIRNA INHIBITORS FOR PREVENTING AND TREATING ANEURYSMS, HYPERTENSION, ARDS AND OTHER DISEASES ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION
#220METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
#221Methods and Compositions for Adar-Mediated Editing
#222ANTISENSE OLIGOMERS FOR TREATMENT OF NON-SENSE MEDIATED RNA DECAY BASED CONDITIONS AND DISEASES
#223ANTISENSE OLIGONUCLEOTIDE TARGETING CAV3.1 GENE AND USES THEREOF
#224Modulators of Complement Factor B
#225NOVEL lncRNA CONTROLLING CARDIAC FIBROSIS
#226METHOD FOR DESIGNING OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY
#227CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#228COMB SHAPED ANTIVIRALS ENDING WITH OR WITHOUT CHAIN TERMINATING BASES
#229COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA
#230TUNING CRISPR/CAS9 ACTIVITY WITH CHEMICALLY MODIFIED NUCLEOTIDE SUBSTITUTIONS
#231COMPOSITIONS OF MATTER FOR DETECTION ASSAYS
#232OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES
#233MULTICOMPONENT XNAZYME-BASED NUCLEIC ACID DETECTION SYSTEM
#234COMPOSITIONS, SYSTEMS AND METHODS FOR ENZYME OPTIMIZATION
#235NOVEL PEPTIDE-OLIGONUCLEOTIDE CONJUGATE AND USE THEREOF
#236GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT
#237MICRORNA BLOCKADE FOR THE TREATMENT OF DISEASE
#238ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTELl EXPRESSION
#239MICRORNA-27B INHIBITORS
#240TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
#241CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
#242ANTISENSE OLIGONUCLEOTIDES TARGETING FOXG1
#243METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#244ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT
#245Selective Antisense Compounds and Uses Thereof
#246ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF CORNEAL DYSTROPHIES
#247Oligonucleotide Comprising Inosine for Treating DMD
#248RNA MOLECULE, CHIMERIC NA MOLECULE, DOUBLE-STRANDED RNA MOLECULE, AND DOUBLE-STRANDED CHIMERIC NA MOLECULE
#249COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA
#250MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
#251MODIFIED HETERO NUCLEIC ACIDS
#252COMPOSITIONS AND METHODS FOR TREATING PULMONARY ARTERIAL HYPERTENSION (PAH) AND OTHER DISORDERS
#253SUBSTANCES AND METHODS FOR TREATING DYSTROPHIC EPIDERMOLYSIS BULLOSA
#254Compounds and methods for modulating SCN2A
#255MODULATION OF AAV-BASED GENE EXPRESSION
#256COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#257OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
#258ANTISENSE OLIGOMERS TARGETING PCSK9
#259Novel Synthesis of Phosphorodithioate Oligonucleotides
#260ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9
#261METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
#262COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIAC DISEASES
#263Compounds and methods for modulating ATXN1
#264ANTISENSE COMPOUNDS
#265PHARMACEUTICAL COMPOSITION
#266Oligomers and oligomer conjugates
#267Compositions of matter for detection assays
#268COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#269OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
#270COMPOUNDS AND METHODS FOR MODULATING SCN2A
#271VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF
#272SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES
#273METHODS AND COMPOSITIONS FOR RESTORING STMN2 LEVELS
#274TREATMENT OF FUCHS' ENDOTHELIAL CORNEAL DYSTROPHY
#275bZIP TRANSCRIPTION FACTORS REGULATE CONVERSION OF NICOTINE TO NORNICOTINE
#276UMLILO ANTISENSE TRANSCRIPTION INHIBITORS
#277GUIDE RNA WITH CHEMICAL MODIFICATIONS
#278Compositions of matter for detection assays
#279EXOSOMAL LOADING USING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDES
#280SELECTIVE RNA-MODULATING AGENTS
#281MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF
#282TARGETING XIST AND RNA METHYLATION FOR X REACTIVATION THERAPY
#283Human XIST Antisense Oligonucleotides for X Reactivation Therapy
#284COMBINATION
#285Modified short interfering nucleic acid (siNA) molecules and uses thereof
#286COMPOUNDS AND METHODS FOR REDUCING APOE EXPRESSION
#287METHODS TO RE-ENGAGE A FETAL WOUND HEALING PATHWAY FOR ADULT SKIN REPAIR
#288ANTISENSE OLIGONUCLEOTIDES FOR MODULATION OF LONG NONCODING RNAS
#289DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDES
#290RNA Interactome of Polycomb Repressive Complex 1 (PRC1)
#291SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
#292OLIGONUCLEOTIDES
#293Compositions of matter for detection assays
#294TREATMENT OF SKIN DISEASES AND DISORDERS USING INHIBITORS OF KALLIKREIN-RELATED PEPTIDASES (KLK)
#295Compositions and methods of treating facioscapulohumeral muscular dystrophy
#296TEMPLATE GUIDE RNA MOLECULES
#297Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
#298TREATMENT AND DETECTION OF LIVER FIBROSIS AND LIVER DISEASE USING MICRORNA
#299BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF
#300OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION